A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
← catalyst calendarSponsored by ALX Oncology Inc. (industry) · ALXO — their whole pipeline →. With Eli Lilly and Company.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
127actual
Sites
83
Countries
Australia, Belgium, Czechia +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-01-15 | actual | When the study began enrolling |
| Primary completion | 2024-05-24 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-08-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma
Interventions
- Drug: Evorpacept (ALX148)
- Drug: Trastuzumab — also filed as Herceptin
- Drug: Ramucirumab — also filed as Cyramza
- Drug: Paclitaxel — also filed as Taxol
Primary outcomes
what the primary-completion date above is the date OFPhase 2
measured Last randomized patient on study at least 16 weeks
Phase 3
measured From the date of randomization to the date of death (due to any cause), up to 36 months postdose
Permalink · ALXO's whole pipeline · Catalyst calendar · Every registered study · What changed